Pursue Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Pursue Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$294K	Hold	591	–	–	0.16%	81
2026 Q1	$264K	Hold	591	–	–	0.16%	87
2025 Q4	$268K	Hold	591	–	–	0.13%	89
2025 Q3	$231K	Hold	591	–	–	0.13%	105
2025 Q2	$263K	Hold	591	–	–	0.15%	96
2025 Q1	$287K	Hold	591	–	–	0.17%	86
2024 Q4	$238K	Hold	591	–	–	0.14%	100
2024 Q3	$275K	Hold	591	–	–	0.15%	90
2024 Q2	$277K	Hold	591	–	–	0.15%	82
2024 Q1	$247K	Hold	591	–	–	0.15%	93
2023 Q4	$240K	Hold	591	–	–	0.16%	80
2023 Q3	$206K	Sell	591 -43	-7%	-$15K	0.15%	86
2023 Q2	$223K	Buy	+634	New	+$214K	0.14%	92
2022 Q2	–	Sell	-591	Closed	-$163K	–	242
2022 Q1	$163K	Buy	+591	New	+$140K	0.07%	141

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Pursue Wealth Partners's VRTX Position: Q2 2026 in Review

Pursue Wealth Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 591 shares worth $294K. The position accounts for 0.16% of the portfolio, ranked #81.

Pursue Wealth Partners first reported a position in VRTX in Q1 2022 and has held it in 14 quarters since. 1,759 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Pursue Wealth Partners held 591 shares of Vertex Pharmaceuticals worth $294K as of Q2 2026.
Pursue Wealth Partners left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.16% of Pursue Wealth Partners's portfolio in Q2 2026, its #81 holding.
Pursue Wealth Partners first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
1,759 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Pursue Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.